Related Experiment Video
Updated: Apr 26, 2026

07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
7.0K
CMAP-Fusion: A cross-modal feature selection and model pruning framework for laboratory and imaging data
Chong Liu1, Lei Yang2, Jinmeng Lei3
1Senior Engineer, Liuzhou Women and Children's HealthCare Hospital, Liuzhou, Guangxi, China.
Plos One
|April 24, 2026
Summary
The novel Cross-Modal Alignment-Pruning Fusion (CMAP-Fusion) model enhances medical diagnosis by effectively integrating imaging and lab data, improving accuracy and efficiency while reducing computational costs.
Area of Science:
- Medical Imaging
- Artificial Intelligence
- Data Fusion
Background:
- Cross-modal fusion of medical imaging and laboratory data is crucial for disease diagnosis.
- Existing methods face challenges like modal heterogeneity, feature redundancy, and efficiency imbalance, limiting precision and clinical adaptability.
Purpose of the Study:
- To propose the Cross-Modal Alignment-Pruning Fusion (CMAP-Fusion) model for optimized medical cross-modal fusion.
- To address limitations in precision, efficiency, and generalization of current fusion techniques.
Main Methods:
- Utilized Vision Transformer (ViT-B/16) for imaging feature extraction and dimension alignment.
- Implemented the SmartTrim dynamic pruning module to screen key features and reduce redundancy.
- Employed the Cross-Modal Transformer (CMT) to mine deep associations between dual modalities.
Main Results:
- Achieved high accuracies: 95.3% (COVID-19), 89.7% (ISIC Skin Cancer), 93.6% (ChestX-ray14).
- Improved accuracy by 3.1%-4.1% over optimal baselines.
- Reduced parameters by 44.2% and computational complexity by over 43%.
Conclusions:
- CMAP-Fusion synergistically optimizes precision, efficiency, and generalization for medical cross-modal fusion.
- The model offers an efficient solution, outperforming baselines in accuracy, efficiency, and feature representation.
- Future work includes expanding to multi-source modalities, multi-disease scenarios, and clinical validation.